Your browser doesn't support javascript.
loading
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem, Aishath; Utro, Filippo; Wang, Qing; Cha, Justin; Vihinen, Mauno; Martindale, Stephen; Zhou, Yinglu; Ren, Yue; Tyekucheva, Svitlana; Kim, Annette S; Fernandes, Stacey M; Saksena, Gordon; Rhrissorrakrai, Kahn; Levovitz, Chaya; Danysh, Brian P; Slowik, Kara; Jacobs, Raquel A; Davids, Matthew S; Lederer, James A; Zain, Rula; Smith, C I Edvard; Leshchiner, Ignaty; Parida, Laxmi; Getz, Gad; Brown, Jennifer R.
Afiliação
  • Naeem A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Utro F; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.
  • Wang Q; IBM Research, Yorktown Heights, New York, NY.
  • Cha J; Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86, Huddinge, Sweden.
  • Vihinen M; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.
  • Martindale S; Department of Experimental Medical Science, Lund University, SE-221 84, Lund, Sweden.
  • Zhou Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Ren Y; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA.
  • Tyekucheva S; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA.
  • Kim AS; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA.
  • Fernandes SM; Department of Pathology, Brigham and Women's Hospital, Boston, MA.
  • Saksena G; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Rhrissorrakrai K; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.
  • Levovitz C; IBM Research, Yorktown Heights, New York, NY.
  • Danysh BP; IBM Research, Yorktown Heights, New York, NY.
  • Slowik K; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.
  • Jacobs RA; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.
  • Davids MS; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.
  • Lederer JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Zain R; Department of Medicine, Brigham and Women's Hospital, Boston, MA.
  • Smith CIE; Department of Surgery, Brigham and Women's Hospital, Boston, MA.
  • Leshchiner I; Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86, Huddinge, Sweden.
  • Parida L; Centre for Rare Diseases, Department of Clinical Genetics, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.
  • Getz G; Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86, Huddinge, Sweden.
  • Brown JR; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.
Blood Adv ; 7(9): 1929-1943, 2023 05 09.
Article em En | MEDLINE | ID: mdl-36287227
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B Idioma: En Ano de publicação: 2023 Tipo de documento: Article